For BIG, revenue is more important than profitability as it position itself as a acquisition target.

The following 2 paragraphs are extracted from OCBC Research :

Market share vs. profitability.

Biosensors' gross margins have and will continue to improve due to 1) sales increase in high margin DES products; 2) better optimisation in balancing direct sales force vs. distributors and; 3)greater efficiencies from its operations. We continue to adhere to our stance that Biosensors will fixate on gaining market share (growing revenue) in the near term vs. cutting costs to attain profitability. This is to gain elevated market presence and to eventually position itself for an acquisition.

Good company, but better target.

While we agree that Biosensors has breakthrough technology, we are mindful that the medtech world continually sees consolidation. As an acquisition target, significant accretion to an acquirer's market share and technology pipeline outweighs profitability concerns. Although details were lacking due to competitive reasons, management updated that its next-gen BioMatrix-Freedom polymer-free DES continues to garner good feedback. Our checks in the US Patent database shows Biosensors' Freedom stent patent was filed on 21 May 2007.

 Note : The guidance (regarding profitability) given in late 2007 is no longer valid due to the failed JWMS deal.

True revenue is secondary, profits is just about everything. They did give guidance in late 2007. Sorry I dun have them now but I did post it last year. I specifically remember them saying that they would be cashflow positive sometime in 2009. Bengster then gave his version of wat the guidance should have been, much to my chagrin. Well, good things come to those who wait. 

of course revenue up is a good sign , but you also must generate profits, else, what for good revenue with negative profits?

or at least they should tell us when to turn profit la... no patience liao lei..  arrgghh...

BIG did ok. Why is everyone jumping at their loss? Quite good actually.